Glaucoma Drug Gets New Indication for Skimpy Eyelashes
IRVINE, Calif. (MedPage Today) — The FDA has approved the glaucoma drug bimatoprost for treatment of eyelash hypotrichosis — lashes that are not long, thick, or dark enough — the drug’s maker announced here.
See the article here:
Glaucoma Drug Gets New Indication for Skimpy Eyelashes
FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Inc, maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse
See the rest here:
FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…
IRVINE, Calif.–(BUSINESS WIRE)–Dec 26, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.
A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva®)
(Source: International Journal of Dermatology)
Original post:
A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva®)
FDA OKs Latisse For Hypotrichosis of Eyelashes Treatment
New prescription drug Latisse increases the length, thickness and darkness of eyelashes. (Source: Huliq Health News)
Read more from the original source:
FDA OKs Latisse For Hypotrichosis of Eyelashes Treatment
Allergan Eyelash Enhancer Approved
Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma. (Source: WSJ.com: Health)
Read the original post:
Allergan Eyelash Enhancer Approved
LATISSEâ„¢ – New Prescription Product Increases Length, Thickness And Darkness Of Eyelashes
Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) has approved LATISSEâ„¢ (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.
Follow this link:
LATISSEâ„¢ – New Prescription Product Increases Length, Thickness And Darkness Of Eyelashes
Glaucoma Drug Doubles As Eyelash Enhancer
A panel of government experts said Friday a glaucoma drug from Allergan appears to be a safe and effective way to make eyelashes longer and fuller. (Source: Health News: CBSNews.com)
Go here to see the original:
Glaucoma Drug Doubles As Eyelash Enhancer
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
IRVINE, Calif.–(BUSINESS WIRE)–Dec 5, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve Latisse…
Hypotrichosis Of Eyelashes – FDA Advisory Committee Unanimously Recommends Approval Of LATISSEâ„¢ (Bimatoprost Solution 0.03%)
Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve LATISSEâ„¢ (bimatoprost solution 0.03%) as a treatment for hypotrichosis (or reduced amount of hair) of the eyelashes
Follow this link:
Hypotrichosis Of Eyelashes – FDA Advisory Committee Unanimously Recommends Approval Of LATISSEâ„¢ (Bimatoprost Solution 0.03%)
FDA OKs Drug for Enhancing Eyelashes
Allergan’s glaucoma solution may see more lucrative use on the cosmetic scene. (Source: ABC News: Health) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network , and receive $5 free advertising.
View post:
FDA OKs Drug for Enhancing Eyelashes
Allergan eyelash drug wins U.S. panel backing
ROCKVILLE, Maryland (Reuters) – An Allergan Inc glaucoma drug is safe and effective enough for U.S.
See the original post:
Allergan eyelash drug wins U.S. panel backing